Sign in →

Test Code AGA Alpha-Galactosidase, Leukocytes

Reporting Name

Alpha-Galactosidase, Leukocytes

Performing Laboratory

Mayo Medical Laboratories in Rochester

Method Name


Testing Algorithm

The following algorithms are available in Special Instructions:

-Fabry Disease: Newborn Screen-Positive Follow-up

-Fabry Disease Testing Algorithm

Specimen Type

Whole Blood ACD

Specimen Required

Specimen must arrive within 72 hours of draw to be stabilized. Specimen received after 72 hours could have falsely normal results. Draw specimen Monday through Thursday only and not the day before a holiday. Specimen should be drawn and packaged as close to shipping time as possible.



Preferred: Yellow top (ACD solution B)

Acceptable: Yellow top (ACD solution A)

Specimen Volume: 7 mL

Collection Instructions: Do not transfer blood to other containers.


1. New York Clients-Informed consent is required. Please document on the request form or electronic order that a copy is on file. An Informed Consent for Genetic Testing (Supply T576) is available in Special Instructions.

2. If not ordering electronically, submit a Biochemical Genetics Request Form (Supply T439) with the specimen.

Specimen Minimum Volume

6 mL

Specimen Stability Information

Specimen Type Temperature Time
Whole Blood ACD Refrigerated (preferred) 72 hours
  Ambient  72 hours

Reject Due To


Mild OK; Gross reject







Reference Values

≥23.1 nmol/hour/mg protein

An interpretative report will be provided.

Note: Results from this assay do not reflect carrier status because of individual variation of alpha-galactosidase enzyme levels.

Day(s) and Time(s) Performed

Specimens are processed Monday through Sunday.

Assay is performed on Tuesday.

Analytic Time

8 days

Specimen Retention Time

WBC homogenate stored 1 month

Useful For

Diagnosis of Fabry disease in males  


Verifying abnormal serum alpha-galactosidase results in males with a clinical presentation suggestive of Fabry disease


Deficiency of alpha-galactosidase A (alpha-Gal A) is diagnostic for Fabry disease in males.


Urine sediment analysis (CTSA / Ceramide Trihexoside/Sulfatide Accumulation in Urine Sediment, Urine) for the accumulating trihexoside substrate is also recommended.


Carrier females usually have alpha-galactosidase levels in the normal range; therefore, molecular sequence analysis of the GLA gene (FABMS / Fabry Disease, Full Gene Analysis) is recommended as the appropriate diagnostic test for females.

Test Classification

This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the U.S. Food and Drug Administration.

CPT Code Information


LOINC Code Information

Result ID Reporting Name LOINC Code
32302 Reason for Referral 42349-1
32303 Method 49549-9
8785 Alpha-Galactosidase, Leukocytes 24049-9